Redeye’s first comments follow this morning’s Q2 report from Tagmaster, which again showed lower org...
Redeye comments on Climeon’s Q2 figures being without any material income in the quarter, which was ...
Redeye provides its initial take on Vitec’s Q2 2024 report, which mostly exceeded our estimates.
Redeye sees a solid Q2 report from Fortnox, with strong net customer intake and high growth in Core ...
Redeye sees that BONESUPPORT is well-equipped to surpass its new 50% 2024e sales growth target, and ...
- Adj. EBITA SEK 215m (-3% vs. ABGSCe 222m) - Consensus full-year EBITA likely down marginally - 12x...
Q-linea and its distribution partners continue to advance pilot and tender process activities, which...
XVIVO delivered a positive surprise in Q2 with organic growth of 35% which was well ahead of the alr...
Redeye comments on Alligators Q2 report and updates its base case.
Redeye updates its estimates ahead of Arise’s Q2 report, which is due on 17 July.
Ascelia proceeds with a rights issue of units to secure growth capital to be able to finalize and su...
Redeye raised its Base Case and 2025 forecasts for Transtema following the recently announced large ...
Redeye leaves a note following Faron’s announcement of positive feedback from its meeting with the F...
Det höga ränteläget fortsätter att påverka förvaltningsresultatet negativt, men väntas förbättras i ...
Redeye leaves a short comment following Kancera's announcement from earlier this morning regarding c...
Q-linea has reduced the OPEX by SEK 50m annually, suggesting a reduced OPEX run-rate to SEK 40-45m.
- We expect continued strong order intake momentum - Minor estimate changes - NTM EV/EBIT around 9x ...
- We cut '25e-'26e EBIT by 2%... - ...and still expect no organic growth in '24e - Trading at NTM EV...
- FTX claim sold and FlowBank investment impaired - We increase adj.
Redeye provides an update on Circio and a new base case after the rights issue.
